Tetra Radar · FDA Approvals · Decision date
Quimilza: FDA decision date
Vanda Pharmaceuticals Inc (VNDA) · 12 December 2026
The Biologics License Application (BLA) for Quimilza™ in Generalized Pustular Psoriasis (GPP) is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026.
Source: 10-Q of 29 October 2026
The decision is pending.
Vanda Pharmaceuticals Inc on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.